A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients

Inclusion Criteria: * ECOG performance status of 0 to 1. * Life expectancy of more than 12 weeks. * Histologically or cytologically confirmed gastric adenocarcinoma( adenocarcinoma of the gastroesophageal junction included). * Recurrent or metastatic gastric cancer that has progressed following first line-therapy. * At least one lesion (measurable and/or non-measurable) that can be accurately assessed by imaging (CT/MRI) at baseline * Subjects who have overall good overall general condition. * Signed informed consent. Exclusion Criteria: * Subjects who received any previous treatment with any PARP inhibitors. * Subjects who received any previous treatment with any taxanes. * More than one prior chemotherapy regimen for the treatment of gastric cancer in the metastatic or recurrent setting. * Less than 4 weeks from the last clinical trial. * Less than 2 weeks from the last radiotherapy, chemotherapy, surgery, hormone treatment and target therapy. * Unstable hypertension. * Subjects that are unable to swallow, or dysfunction of gastrointestinal absorption. * Subjects with brain metastases. * Subjects with uncontrolled hypokalemia and hypomagnesemia before study entry. * Subjects with a known hypersensitivity to fluzoparib, apatinib, paclitaxel or any of the excipients of the product. * Ongoing infection (determined by investigator). * History of immunodeficiency, including HIV-positive, suffering from other acquired, congenital immunodeficiency disease, or history of organ transplantation. * Subjects who can not interrupt the using of the drugs that may cause QT prolongation during study. * Pregnant or breast-feeding women.